Sunesis Pharmaceuticals Inc. [NASDAQ: SNSS] surged by $0.19 during the normal trading session on Friday and reaching a high of $1.48 during the day while it closed the day at $1.36.
Sunesis Pharmaceuticals Inc. stock has also loss -10.53% of its value over the past 7 days. However, SNSS stock has declined by -52.28% in the 3 months of the year. Over the past six months meanwhile, it has lost -67.62% and lost -59.73% year-on date.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The market cap for SNSS stock reached $21.20 million, with 111.39 million shares outstanding and 65.91 million shares in the current float. Compared to the average trading volume of 1.63M shares, SNSS reached a trading volume of 3404549 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Sunesis Pharmaceuticals Inc. [SNSS]:
Oppenheimer have made an estimate for Sunesis Pharmaceuticals Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on June 24, 2020. While these analysts kept the previous recommendation, Wells Fargo dropped their target price from $3 to $1. The new note on the price target was released on March 11, 2020, representing the official price target for Sunesis Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Sunesis Pharmaceuticals Inc. is set at 0.20, with the Price to Sales ratio for SNSS stock in the period of the last 12 months amounting to 9.64. The Price to Book ratio for the last quarter was 3.49.
SNSS stock trade performance evaluation
Sunesis Pharmaceuticals Inc. [SNSS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.53. With this latest performance, SNSS shares dropped by -53.22% in over the last four-week period, additionally sinking by -67.62% over the last 6 months – not to mention a drop of -83.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNSS stock in for the last two-week period is set at 35.41, with the RSI for the last a single of trading hit 38.19, and the three-weeks RSI is set at 35.99 for Sunesis Pharmaceuticals Inc. [SNSS]. The present Moving Average for the last 50 days of trading for this stock 2.5028, while it was recorded at 1.3060 for the last single week of trading, and 4.2779 for the last 200 days.
Sunesis Pharmaceuticals Inc. [SNSS]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sunesis Pharmaceuticals Inc. [SNSS] shares currently have an operating margin of -1123.40. Sunesis Pharmaceuticals Inc.’s Net Margin is presently recorded at -1125.42.
Return on Total Capital for SNSS is now -103.01, given the latest momentum, and Return on Invested Capital for the company is -146.69. Return on Equity for this stock declined to -147.96, with Return on Assets sitting at -88.77. When it comes to the capital structure of this company, Sunesis Pharmaceuticals Inc. [SNSS] has a Total Debt to Total Equity ratio set at 22.81. Additionally, SNSS Total Debt to Total Capital is recorded at 18.57, with Total Debt to Total Assets ending up at 16.87. Long-Term Debt to Equity for the company is recorded at 1.72, with the Long-Term Debt to Total Capital now at 0.80.
Reflecting on the efficiency of the workforce at the company, Sunesis Pharmaceuticals Inc. [SNSS] managed to generate an average of -$972,083 per employee.Sunesis Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.60.
Earnings per share (EPS) analysis for Sunesis Pharmaceuticals Inc. [SNSS] stock
With the latest financial reports released by the company, Sunesis Pharmaceuticals Inc. posted -0.6/share EPS, while the average EPS was predicted by analysts to be reported at -0.85/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 29.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNSS.
Sunesis Pharmaceuticals Inc. [SNSS]: Insider Ownership positions
There are presently around $5 million, or 24.60% of SNSS stock, in the hands of institutional investors. The top three institutional holders of SNSS stocks are: AISLING CAPITAL MANAGEMENT LP with ownership of 1,010,000, which is approximately 0% of the company’s market cap and around 0.18% of the total institutional ownership; NANTAHALA CAPITAL MANAGEMENT, LLC, holding 956,684 shares of the stock with an approximate value of $1.3 million in SNSS stocks shares; and VANGUARD GROUP INC, currently with $0.57 million in SNSS stock with ownership of nearly -1.333% of the company’s market capitalization.
Positions in Sunesis Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 13 institutional holders increased their position in Sunesis Pharmaceuticals Inc. [NASDAQ:SNSS] by around 72,207 shares. Additionally, 23 investors decreased positions by around 3,039,880 shares, while 18 investors held positions by with 666,973 shares. The mentioned changes placed institutional holdings at 3,779,060 shares, according to the latest SEC report filing. SNSS stock had 7 new institutional investments in for a total of 37,237 shares, while 13 institutional investors sold positions of 2,612,333 shares during the same period.